Last Updated: November 16, 2026

List of Excipients in Branded Drug VILAZODONE HYDROCHLORIDE

« Back to Dashboard


Generic Drugs Containing VILAZODONE HYDROCHLORIDE

Vilazodone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Vilazodone hydrochloride is an off-patent oral antidepressant with formulation opportunities centered on food-dependent absorption, low aqueous solubility, tablet manufacturability, and differentiated administration. The branded product, Viibryd, uses a conventional immediate-release film-coated tablet. The strongest near-term commercial opportunities are low-cost generic supply, orally disintegrating or sprinkle formulations, solubility-enhanced products, and excipient systems that reduce variability when patients do not take the drug with a meal.

What is the current commercial and regulatory status of vilazodone hydrochloride?

Vilazodone hydrochloride is approved in the United States for the treatment of major depressive disorder in adults. Forest Laboratories launched Viibryd in 2011; the product is now associated with AbbVie following the acquisition of Allergan. The FDA-approved strengths are 10 mg, 20 mg, and 40 mg tablets.[1]

Item Status
Active ingredient Vilazodone hydrochloride
Brand Viibryd
Dosage form Immediate-release film-coated tablet
FDA approval 2011
Approved indication Major depressive disorder in adults
Standard titration 10 mg, 20 mg, then 40 mg daily
Administration Once daily with food
Market status Generic competition available
Primary formulation issue Food-dependent absorption
Regulatory route for new products ANDA or 505(b)(2), depending on formulation and claims

The FDA label requires administration with food. Vilazodone exposure is materially lower under fasting conditions, making administration behavior a central formulation and commercial issue.[1] A formulation that produces more consistent exposure across fed and lightly fed conditions could support a differentiated product, although it would require clinical bridging and FDA review.

What excipients are used in the Viibryd formulation?

The Viibryd tablet uses a standard compressed-tablet platform. The core inactive ingredients are colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The film coating contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc.[1]

Functional role Viibryd excipient or excipient class Formulation purpose
Diluent Lactose monohydrate, microcrystalline cellulose Tablet mass and compressibility
Disintegrant Sodium starch glycolate Tablet breakup after ingestion
Glidant Colloidal silicon dioxide Powder flow and content uniformity
Lubricant Magnesium stearate Ejection and tooling protection
Film former Polyvinyl alcohol Coating structure
Plasticizer or coating aid Polyethylene glycol Coating flexibility
Opacifier and pigment Titanium dioxide Appearance and light protection
Anti-tacking agent Talc Coating-process performance

This composition creates a relatively accessible generic-development target. None of the principal excipients is technically unusual, and the dosage form does not require a specialized delivery device. The main development risks are blend uniformity at the 10 mg strength, dissolution performance, food-effect comparability, and control of tablet hardness without delayed disintegration.

How should an excipient strategy address vilazodone’s food effect?

The preferred strategy depends on whether the objective is a standard generic, a lower-cost manufacturing platform, or a differentiated 505(b)(2) product.

Strategy 1: Conventional immediate-release generic

A conventional generic can replicate the functional excipient architecture without duplicating every inactive ingredient. The formulation target is therapeutic equivalence under FDA bioequivalence requirements, including fed administration where applicable.

Priority development variables are:

  1. Particle-size distribution of vilazodone hydrochloride.
  2. Drug loading uniformity at 10 mg.
  3. Magnesium stearate concentration and lubrication time.
  4. Sodium starch glycolate grade and intragranular versus extragranular placement.
  5. Dissolution across acidic and near-neutral media.
  6. Tablet coating weight and moisture protection.

A direct-compression platform could reduce manufacturing cost if the API has adequate flow and compressibility. Wet granulation may provide better content uniformity and tablet robustness, particularly for the 10 mg strength, but adds processing cost and potential moisture exposure.

Strategy 2: Solubility-enhanced immediate-release tablet

Vilazodone’s food-dependent absorption creates a commercial rationale for excipients that improve wetting, dispersion, and dissolution. Candidate technologies include:

  • Surfactant-assisted tablets using sodium lauryl sulfate or poloxamers.
  • Co-processed excipients that improve powder flow and tablet breakup.
  • Amorphous solid dispersions using polymers such as hypromellose or copovidone.
  • Cyclodextrin complexes.
  • Nanocrystal or micronized API systems.
  • Lipid-based self-emulsifying systems compressed into tablets or filled into capsules.

A surfactant or polymer system may improve dissolution without creating a new dosage form. The principal risk is that enhanced dissolution does not necessarily eliminate the clinical food effect. FDA bioequivalence studies would still determine whether the formulation produces comparable exposure under fed and fasting conditions.

Strategy 3: Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty, psychiatric polypharmacy, and adherence. Suitable excipient systems would likely include mannitol or a mannitol-based co-processed filler, crospovidone, low-substituted hydroxypropyl cellulose, and a taste-masking system.

Vilazodone hydrochloride may have a bitter or unpleasant taste profile. Taste masking could use polymeric coating, ion-exchange resin complexes, cyclodextrins, or lipid barriers. The formulation must preserve rapid oral dispersion without materially changing systemic exposure.

An orally disintegrating tablet would not automatically eliminate the requirement to take the drug with food. Unless clinical data establish otherwise, labeling would likely retain the food-administration instruction.

Strategy 4: Sprinkle or multiparticulate formulation

A sprinkle formulation could target patients who cannot swallow tablets. The commercial options include coated multiparticulates, capsules containing granules, or sachets.

This route has higher development complexity because particle coating, dose uniformity, taste, and administration through soft food or liquid must be controlled. It may qualify for 505(b)(2) treatment if the product differs materially from the approved tablet in dosage form or administration method.

What formulation patents protect vilazodone hydrochloride products?

The principal commercial patent barrier for vilazodone was the compound and pharmaceutical-composition patent estate associated with the original development program. The key U.S. patent commonly associated with vilazodone was U.S. Patent No. 7,834,020, which covered vilazodone-related pharmaceutical compositions and had an expiration date in 2022, subject to applicable patent-term adjustments or extensions.[2]

The relevant distinction for excipient developers is between:

  • Compound patents, which protect the active molecule.
  • Composition patents, which may cover vilazodone formulations.
  • Method-of-use patents, which may cover treatment methods.
  • Manufacturing patents, which may cover synthesis, intermediates, or crystalline forms.
  • Formulation-specific patents, which may cover an ODT, modified-release product, particle-size range, or solubility-enhanced system.

The commercial significance of a formulation patent depends on whether the claim requires a narrow excipient combination, a dissolution profile, a particle-size range, a solid-state form, or a specific pharmacokinetic result. A formulation that uses common excipients but produces a claimed dissolution or exposure profile may still create infringement risk.

What is the Orange Book status of Viibryd and generic vilazodone?

Viibryd’s original regulatory exclusivity has expired, and generic vilazodone products have entered the U.S. market. The FDA Orange Book remains the controlling source for currently listed patents and exclusivity information.[3]

Regulatory issue Commercial implication
New chemical entity exclusivity Expired
Original product exclusivity Expired
Compound patent barrier Expired or no longer blocking ordinary generic entry
Generic pathway ANDA for equivalent immediate-release tablets
Differentiated dosage form Potential 505(b)(2) pathway
Paragraph IV relevance Primarily historical for the original listed patents
Current generic entry barrier Bioequivalence, CMC, supply, and commercial scale

Paragraph IV litigation was relevant to the first-wave generic entrants before expiration of the principal listed patents. For current conventional tablets, the practical barriers are less likely to be the original compound patent and more likely to be formulation-specific patents, regulatory timing, product quality, supply reliability, and market pricing.

Current Orange Book listings should be reviewed by product and patent number before launching a new formulation. Patent status can change through expiration, delisting, pediatric extensions, terminal disclaimers, or court decisions.

Which companies are challenging or competing with Viibryd?

The U.S. competitive field includes branded Viibryd and multiple generic manufacturers. Generic participation has included major and specialty pharmaceutical companies that received or pursued approvals for vilazodone hydrochloride tablets. Competitive intensity is highest for the 20 mg and 40 mg strengths, which represent the principal maintenance doses.

The commercial market is influenced by:

  • Wholesale acquisition price.
  • Wholesaler and pharmacy contracting.
  • Generic manufacturer count.
  • Medicaid and Medicare formulary placement.
  • Back-order frequency.
  • Ability to supply all three strengths.
  • Product availability in 90-count and 30-count configurations.
  • Pharmacist substitution rules.

A new conventional tablet is likely to face rapid price compression. A differentiated formulation has a stronger opportunity if it addresses adherence, swallowing, food-related dosing, or supply reliability.

What manufacturing and intellectual-property barriers affect excipient opportunities?

The most material technical barrier is controlling low-dose content uniformity. The 10 mg tablet contains a relatively small amount of active ingredient compared with the total tablet mass. API particle-size control, ordered mixing, geometric dilution, or granulation may be needed to meet uniformity requirements.

Other barriers include:

  • API polymorph and solid-state control.
  • Moisture sensitivity during granulation and coating.
  • Magnesium stearate over-lubrication.
  • Dissolution changes caused by particle-size reduction.
  • Taste masking in orally disintegrating products.
  • Excipient compatibility with vilazodone hydrochloride.
  • Scale-up of polymer or lipid systems.
  • Stability under high humidity.
  • Residual solvent control for spray-dried dispersions.

Manufacturing-related patents may be more relevant to API suppliers than to conventional finished-dose manufacturers. An excipient supplier can create value through a proprietary co-processed filler, taste-masking system, or solubility-enhancing platform, but the commercial protection will depend on patent claims that cover composition, process, or performance rather than a merely preferred excipient.

How does vilazodone compare with competing antidepressant opportunities?

Vilazodone differs from many generic SSRIs because its label includes a specific food-administration requirement. That creates a formulation opportunity absent from drugs with less pronounced food effects.

Product characteristic Vilazodone Conventional SSRI generic
Food instruction Required with food Often less restrictive
Standard product Immediate-release tablet Tablet, capsule, or liquid
Main excipient opportunity Reduce food-related variability Improve swallowing, stability, or cost
Generic price pressure High High
505(b)(2) potential ODT, sprinkle, solubility-enhanced product Depends on drug
Adherence rationale Food coordination and tolerability Usually administration simplicity
Technical focus Dissolution and fed-state exposure Dose uniformity and dosage-form differentiation

Vilazodone therefore offers a narrower but more specific formulation thesis than many antidepressant products. A successful product would need to show a meaningful advantage over a low-cost generic tablet.

What revenue exposure and licensing opportunities exist?

AbbVie does not separately report Viibryd revenue as an independently disclosed line item in its public financial reporting. The product’s commercial value is therefore difficult to isolate from public company filings.[4]

The most realistic licensing opportunities are:

  1. A co-processed excipient platform for generic vilazodone manufacturers.
  2. A solubility-enhanced formulation licensed through a 505(b)(2) partner.
  3. An ODT or sprinkle product licensed to a specialty pharmaceutical company.
  4. A regional commercialization agreement in markets where generic penetration remains limited.
  5. An API-plus-finished-dose supply arrangement with an integrated manufacturer.
  6. A contract-development program for low-cost, three-strength tablet production.

A conventional excipient substitution is unlikely to command a large royalty unless it reduces manufacturing cost, solves a supply problem, or materially improves bioequivalence performance. A differentiated dosage form can support stronger economics, but it requires clinical, regulatory, and market evidence.

How strong is the vilazodone patent estate for a new excipient product?

The estate is relatively weak for an ordinary immediate-release generic because the original product has lost key exclusivity protections and generic products are already available. It is stronger for narrow, technically distinct products that claim:

  • A specific amorphous dispersion.
  • A defined particle-size distribution.
  • A new crystalline or salt form.
  • A food-independent pharmacokinetic profile.
  • A taste-masked ODT.
  • A multiparticulate sprinkle formulation.
  • A defined dissolution profile tied to a specific excipient system.
  • A manufacturing process that produces a controlled solid-state form.

Patent value will depend on claim breadth and freedom-to-operate analysis. Broad claims to vilazodone tablets are less likely to provide meaningful protection than narrowly drafted claims tied to a demonstrated technical effect.

What generic launch scenarios exist for vilazodone?

Low-cost conventional generic

This is the lowest-risk regulatory path and the most competitive commercial path. Success depends on cost, reliable supply, and rapid pharmacy substitution.

Premium generic with improved manufacturing economics

A formulation using co-processed excipients or simplified granulation may support margin improvement, but the product remains exposed to generic price erosion.

505(b)(2) orally disintegrating tablet

This route can create differentiation through administration convenience. The product would require a stronger clinical and intellectual-property position than a standard ANDA.

Food-effect-reduction product

This has the highest strategic value because it addresses the principal label-related limitation. It also carries the highest clinical risk because the sponsor must establish the relevance of the formulation’s pharmacokinetic profile and determine whether labeling can change.

Key Takeaways

  • Vilazodone hydrochloride is a genericized antidepressant with an established immediate-release tablet platform.
  • Viibryd uses common excipients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and a conventional film coat.
  • The main formulation opportunity is food-dependent absorption, not basic tablet manufacture.
  • Conventional generics face substantial price pressure and limited patent leverage.
  • ODT, sprinkle, taste-masked, and solubility-enhanced products offer stronger differentiation.
  • Low-dose content uniformity at 10 mg is a major manufacturing consideration.
  • New products should be screened against current Orange Book listings and formulation-specific patents.
  • The most attractive licensing targets are excipient platforms that improve dissolution, reduce food-related variability, or enable an alternate dosage form.

FAQs

Can vilazodone hydrochloride be formulated as an orally disintegrating tablet?

Yes. An ODT could use mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and a taste-masking system. FDA labeling would likely continue to require administration with food unless clinical data support a revised instruction.

Which excipient is most important for vilazodone tablet disintegration?

Sodium starch glycolate is the principal disintegrant in the branded tablet. Crospovidone is a plausible alternative or complementary disintegrant for a generic or ODT platform.

Does a new excipient combination require a 505(b)(2) application?

Not necessarily. A conventional immediate-release tablet that is pharmaceutically equivalent and bioequivalent may qualify for an ANDA. A materially different dosage form, route, formulation, or labeling claim may require 505(b)(2) treatment.

Can a vilazodone formulation eliminate the food requirement?

Potentially, but not through excipient selection alone. The sponsor would need pharmacokinetic evidence showing comparable exposure under relevant fed and fasting conditions, followed by FDA review of the proposed labeling.

Is a new vilazodone tablet likely to receive meaningful patent protection?

A standard tablet using conventional excipients is unlikely to support broad, commercially powerful protection. A narrow patent strategy is more viable for a defined solid-state form, ODT, multiparticulate system, taste-masking technology, or formulation that demonstrates a measurable pharmacokinetic or dissolution advantage.

References

  1. U.S. Food and Drug Administration. (2023). Viibryd (vilazodone hydrochloride) prescribing information. FDA.

  2. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 7,834,020, pharmaceutical compositions comprising vilazodone. USPTO.

  3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  4. AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. AbbVie.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.